If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/.
A murine IgM monoclonal antibody (MoAb) developed for the potential treatment of graft versus host disease (GvHD). Gavilimomab recognizes human CD147 antigen, weakly expressed on human leukocytes and up-regulated on activated lymphocytes. This MoAb is capable of neutralizing inflammatory reactions via a complement-dependent cytotoxic mechanism. However, gavilimomab does not offer an improvement over antithymocyte globulin in the treatment of acute steroid resistant GVHD. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
